anti-EpCAM CAR T-cell therapy (AffyImmune Therapeutics)

N/A

Report date: 2025/03/14 16:38:31

Base Information

Drug Nameanti-EpCAM CAR T-cell therapy (AffyImmune Therapeutics)
Drug Alias Namemicromolar affinity tuned anti-EpCAM CAR T-cells (AffyImmune Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionEpithelial cell adhesion molecule modulators
TargetsEpithelial cell adhesion molecule
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAffyimmune Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAffyimmune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A